---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-049235"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:18:39.760479+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arvinas Q3 cash $787.6M; vepdegestrant NDA accepted PDUFA June 2026

## Summary
- Cash and securities $787.6M at Sept 30, 2025, down from $1,039.4M at Dec 31, 2024; cash runway into H2 2028.
- R&D expenses $64.7M in Q3 2025 vs $86.9M in Q3 2024, down 26% YoY due to lower program costs.
- FDA accepted NDA for vepdegestrant in ER+/HER2- breast cancer; PDUFA date June 5, 2026.
- ARV-102 Phase 1 showed >90% LRRK2 reduction in PBMCs; no SAEs; multiple dose cohort launched in Parkinson's.
- Repurchased $17.8M of common shares under stock repurchase program in Q3 2025.

## SEC filing metadata
- accession: 0001628280-25-049235
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000162828025049235/0001628280-25-049235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000162828025049235/arvn-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-049235
- JSON: https://secwatch.observer/filing/0001628280-25-049235.json
- Plain text: https://secwatch.observer/filing/0001628280-25-049235.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.